The Impact of BCR-ABL Tyrosine Kinase Inhibitor Therapy on Renal Function in Patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A 2023 Cross-Sectional Study
| dc.contributor.advisor | Addisu M. | |
| dc.contributor.author | Zekarias Seifu | |
| dc.date.accessioned | 2025-08-07T07:26:28Z | |
| dc.date.available | 2025-08-07T07:26:28Z | |
| dc.date.issued | 2024-03-03 | |
| dc.description.abstract | Background: BCR-ABL tyrosine kinase inhibitors are effective in treating various cancers, but concerns exist regarding their potential to cause kidney damage. This study investigated the association between tyrosine kinase inhibitors and renal toxicities in patients at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia. Methods: A hospital-based, cross-sectional study was conducted on 260 patients receiving BCR-ABL tyrosine kinase inhibitors. Data on demographics, diagnoses, treatment characteristics, and laboratory parameters were collected. The primary outcome was the development of adverse renal events, defined as a combination of factors including decreased eGFR by more than 30% from the baseline, significant proteinuria, acute kidney injury, or chronic kidney disease. Logistic regression was used to identify factors associated with AREs. Results: The study observed a statistically significant decrease in eGFR following tyrosine kinase inhibitor treatment. However, the prevalence of adverse renal events (13.1%) was lower than reported in some previous studies. Factors significantly associated with adverse renal events included longer TKI duration, male sex (protective), hypertension, HIV infection, and achieving complete molecular remission or complete hematologic response. No significant associations were found with diabetes mellitus, age, use of ACE inhibitors, or baseline creatinine level. Conclusions: This study suggests that tyrosine kinase inhibitors may decrease eGFR, but the observed risk of adverse renal events was lower than previously reported. However, the relatively small sample size and potential differences in demographics and comorbidities may limit the generalizability of the findings. Further studies with larger sample size along with periodic determinations of renal function, are recommended to solidify these findings. | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/6235 | |
| dc.language.iso | en_US | |
| dc.publisher | Addis Ababa University | |
| dc.subject | therapy on renal function in patients | |
| dc.title | The Impact of BCR-ABL Tyrosine Kinase Inhibitor Therapy on Renal Function in Patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A 2023 Cross-Sectional Study | |
| dc.type | Thesis |